2 results match your criteria: "Research Institute (DW[Affiliation]"
J Pediatr Pharmacol Ther
June 2024
Department of Pharmacy (MR, KG, ML), Children's Minnesota, Minneapolis, MN.
Objectives: Constipation is a common adverse event of opioid use that is often difficult to treat. Methylnaltrexone is a therapeutic option for opioid-induced constipation (OIC) approved for oral and subcutaneous use in adults. These administration routes are not always feasible in the pediatric population.
View Article and Find Full Text PDFJ Pediatr Pharmacol Ther
November 2020
Research Institute (DW, AN), Children's Minnesota, Minneapolis, MN.
Objectives: Enoxaparin has been studied for prophylaxis and treatment of thromboembolism in the pediatric population. Dose-finding studies have suggested higher mean maintenance dose requirements in younger children; however, the current recommended dosing schema endorsed by the American College of Chest Physicians remains conservative, likely secondary to limited data on the safety and efficacy of escalated starting doses. Primary objectives of this study included the identification of patient characteristics and risk factors with associations to anti-factor Xa (anti-Xa) values.
View Article and Find Full Text PDF